Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: A phase II California cancer consortium trial

Clinical Lung Cancer

Volumn 6, Issue 2, 2004, Pages 102-107

  Lara Jr , Primo N ^a   Gumerlock, Paul H ^a   Mack, Philip C ^a   Lau, Derick H M ^a   Gandour Edwards, Regina ^a   Edelman, Martin J ^d   Albain, Kathy S ^e   Law, Lisa Y ^a   Longmate, Jeff ^b   Frankel, Paul ^b   Reddy, Gayatri P ^a   Israel, Valerie ^c   Doroshow, James H ^b   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Neutropenia; p53; Salvage therapy; Second line treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PROTEIN P53;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEG EDEMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES;

EID: 7444257975     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.n.023     Document Type: Article

References (34)

1. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997; 15:2996-3018.
2. Ramalingain S, Belani CP. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 2004; 31(1 suppl 1):68-74.
3. Huisman C, Smit EF, Giaccone G, et al. Second-Line chemotherapy in relapsing or refractory non - small-cell lung cancer: a review. J Clin Oncol 2000; 18:3722-3730.
4. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non - small-cell lung cancer. J Clin Oncol 1995; 3:645-651.
5. Pronzato P, Landucci M, Vaira F, et al. Failure of vinorelbine to produce responses in pretreated non - small-cell lung cancer. Anticancer Res 1994; 14:1413-1415.
6. Furuse K, Ohta M, Fukuoka M, et al. Early phase II clinical study of KW2307 in patients with lung cancer: lung cancer section in KW-2307 Study Group. Gan To Kagaku Ryoho 1994; 21:785-793.
7. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non - small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
8. Fossella FV, DeVore R, Kerr RN, et al. Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non - small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18:2354-2362.
9. Fossella FV, Lippman SM, Tarasoff P, et al. Phase I/II study of gemcitabine, an active agent for advanced non - small-cell long cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14:371 (Abstract #1144).
10. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non - small-cell lung cancer: a phase II study. J Clin Oncol 1994; 1535-1540.
11. Gatzemeri U, Shepherd FA, le Chevalier T, et al. Activity of gemcitabine in patients with non - small-cell lung cancer L a multicentre, extended phase II study. Eur J Cancer 1996; 32:243-248.
12. Anderson H, Lund B, Bach F, et al. Single agent activity of weekly gemcitabine in advanced non - small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1821-1826.
13. Takada M, Negoro S, Kudo S, et al. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study. Cancer Chemother Pharmacol 1998; 41:217-222.
14. Lara PN Jr, Gandara DR, Longmate J, et al. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium trial. Cancer Chemother Pharmacol, 2001; 48:22-28.
15. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Den Haag, The Netherlands: Nijhoff, 1979.
16. Wertz IE, Deitch AD, Gumerlock PH, et al. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol 1996; 27:573-580.
17. Shi XB, Bodner SM, deVere White RW, et al. Identification of p53 mutations in archival prostate tumors. Diagn Mol Pathol 1996; 5:271-278.
18. Lara PN Jr, Lau DHM, Gandara DR. Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol 2002; 3:53-58.
19. Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. J Clin Oncol 1999; 17:2081-2085.
20. van Putten JW, Baas P, Codrington H, et al. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non - small-cell lung cancer. Lung Cancer 2001; 33:289-298.
21. Sculier JP, Lafitte JJ, Berghmans T, et al. A phase II trial testing gemcitabine as second-line chemotherapy for non - small-cell lung cancer. The European Lung Cancer Working Party. Lung Cancer 2000; 29:67-73.
22. Gillenwater HH, Tynan M, Natoli S, et al. Second-line gemcitabine in refractory stage IV non - small-cell lung cancer: a phase II trial. Clin Lung Cancer 2000; 2:133-138.
23. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non - small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597.
24. De Marinis F, Pereira JR, Park K, et al. Does second-line therapy for non-small cell lung cancer (NSCLC) result in symptom palliation? Analysis of 484 patients from a randomized trial of pemetrexed vs docetaxel. Proc Am Soc Clin Oncol 2004; 23:622 (Abstract #7035).
25. Lowe SW, Bodis S, McClatchey A, et al. P53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-810.
26. Lowe SW, Ruleyn HE, Jacks T. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-967.
27. Chiba I, Takahashi T, Nau MM, et al. Mutations in the p53 gene are frequent in primary, resected non - small-cell lung cancer. Oncogene 1990; 5:1603-1610.
28. Takahashi T, Nau MM, Chiba I, et al. P53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246:491-496.
29. Safran H, King T, Choy H, et al. p53 mutations do not predict response to paclitaxel/radiation for non - small-cell lung carcinoma. Cancer 1996; 78:1203-1210.
30. Mitusdomi T, Hamajima N, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a metaanalysis. Clin Cancer Res 2000; 6:4055-4063.
31. Wang Q, Fan S, Eastman A, et al. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996; 88:956-996.
32. Girinsky T, Koumenis C, Graeber TG, et al. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 1995; 55:3726-3731.
33. Shi XB, Di Mauro SM, Highshaw R, et al. Application of a yeast assay to detect functional p53 mutations in archival prostate cancer tissue. Cancer Biother Radiopharm 2002; 17:657-664.
34. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non - small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized Trial of postoperative adjuvant therapy. J Clin Oncol 2001; 19:448-457.